Innate Immune Gene Polymorphisms and COVID-19 Prognosis

COVID-19 is characterized by a heterogeneous clinical presentation and prognosis. Risk factors contributing to the development of severe disease include old age and the presence of comorbidities. However, the genetic background of the host has also been recognized as an important determinant of disease prognosis. Considering the pivotal role of innate immunity in the control of SARS-CoV-2 infection, we analyzed the possible contribution of several innate immune gene polymorphisms (including <i>TLR2</i>-rs5743708, <i>TLR4</i>-rs4986790, <i>TLR4</i>-rs4986791, <i>CD14</i>-rs2569190, <i>CARD8</i>-rs1834481, <i>IL18</i>-rs2043211, and <i>CD40</i>-rs1883832) in disease severity and prognosis. A total of 249 individuals were enrolled and further divided into five (5) groups, according to the clinical progression scale provided by the World Health Organization (WHO) (asymptomatic, mild, moderate, severe, and critical). We identified that elderly patients with obesity and/or diabetes mellitus were more susceptible to developing pneumonia and respiratory distress syndrome after SARS-CoV-2 infection, while the <i>IL18</i>-rs1834481 polymorphism was an independent risk factor for developing pneumonia. Moreover, individuals carrying either the <i>TLR2</i>-rs5743708 or the <i>TLR4</i>-rs4986791 polymorphisms exhibited a 3.6- and 2.5-fold increased probability for developing pneumonia and a more severe disease, respectively. Our data support the notion that the host’s genetic background can significantly affect COVID-19 clinical phenotype, also suggesting that the <i>IL18</i>-rs1834481, <i>TLR2</i>-rs5743708, and <i>TLR4</i>-rs4986791 polymorphisms may be used as molecular predictors of COVID-19 clinical phenotype.